Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BI 425809 Alone or With Itraconazole in Healthy Males
NCT02342717Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve from 0 to 167 hours and Maximum Measured Concentration at 167 hours. Started Jan 2015; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02342717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342717.